Global Bio-chem Technolog... (GBCMY)
Global Bio-chem Technology Statistics
Share Statistics
Global Bio-chem Technology has 177.51M shares outstanding. The number of shares has increased by 21.07% in one year.
| Shares Outstanding | 177.51M |
| Shares Change (YoY) | 21.07% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 2.45B |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 0.88 and the forward PE ratio is null. Global Bio-chem Technology's PEG ratio is -0.01.
| PE Ratio | 0.88 |
| Forward PE | n/a |
| PS Ratio | 0.34 |
| Forward PS | n/a |
| PB Ratio | -0.35 |
| P/FCF Ratio | 8.89 |
| PEG Ratio | -0.01 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Global Bio-chem Technology.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.32, with a Debt / Equity ratio of -1.36.
| Current Ratio | 0.32 |
| Quick Ratio | 0.29 |
| Debt / Equity | -1.36 |
| Debt / EBITDA | 2.04 |
| Debt / FCF | 34.89 |
| Interest Coverage | -0.3 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1.28M |
| Profits Per Employee | $491.13K |
| Employee Count | 1,567 |
| Asset Turnover | 0.44 |
| Inventory Turnover | 8.81 |
Taxes
| Income Tax | -23.98M |
| Effective Tax Rate | -3.22% |
Stock Price Statistics
The stock price has increased by -48.96% in the last 52 weeks. The beta is 0.82, so Global Bio-chem Technology's price volatility has been higher than the market average.
| Beta | 0.82 |
| 52-Week Price Change | -48.96% |
| 50-Day Moving Average | 0.49 |
| 200-Day Moving Average | 0.54 |
| Relative Strength Index (RSI) | 72.69 |
| Average Volume (20 Days) | 42 |
Income Statement
In the last 12 months, Global Bio-chem Technology had revenue of 2B and earned 769.6M in profits. Earnings per share was 4.3.
| Revenue | 2B |
| Gross Profit | 190.97M |
| Operating Income | -95.93M |
| Net Income | 769.6M |
| EBITDA | 1.3B |
| EBIT | 1.07B |
| Earnings Per Share (EPS) | 4.3 |
Balance Sheet
The company has 85.47M in cash and 2.65B in debt, giving a net cash position of -2.57B.
| Cash & Cash Equivalents | 85.47M |
| Total Debt | 2.65B |
| Net Cash | -2.57B |
| Retained Earnings | -8.75B |
| Total Assets | 4.54B |
| Working Capital | -4.39B |
Cash Flow
In the last 12 months, operating cash flow was 76.04M and capital expenditures 0, giving a free cash flow of 76.04M.
| Operating Cash Flow | 76.04M |
| Capital Expenditures | 0 |
| Free Cash Flow | 76.04M |
| FCF Per Share | 0.01 |
Margins
Gross margin is 9.54%, with operating and profit margins of -4.79% and 38.46%.
| Gross Margin | 9.54% |
| Operating Margin | -4.79% |
| Pretax Margin | 37.26% |
| Profit Margin | 38.46% |
| EBITDA Margin | 64.84% |
| EBIT Margin | -4.79% |
| FCF Margin | 3.8% |
Dividends & Yields
GBCMY does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for GBCMY.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -3.51 |
| Piotroski F-Score | 4 |